相似文献
1
Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No.
Mov Disord Clin Pract. 2018 Mar 6;5(2):141-144. doi: 10.1002/mdc3.12582. eCollection 2018 Mar-Apr.
2
Delayed Hypersensitivity Reaction to OnabotulinumtoxinA.
Mov Disord Clin Pract. 2018 Mar 9;5(3):321-322. doi: 10.1002/mdc3.12575. eCollection 2018 May-Jun.
3
Episodic Ataxia Type 1 (K-channelopathy) Manifesting as Paroxysmal Nonkinesogenic Dyskinesia: Expanding the Phenotype.
Mov Disord Clin Pract. 2017 Jul 31;4(5):784-786. doi: 10.1002/mdc3.12518. eCollection 2017 Sep-Oct.
4
Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy.
Neurology. 2001 Apr 10;56(7):957-63. doi: 10.1212/wnl.56.7.957.
5
Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases.
Brain. 2013 Jul;136(Pt 7):2253-61. doi: 10.1093/brain/awt118. Epub 2013 May 31.
6
Does corticobasal degeneration exist? A clinicopathological re-evaluation.
Brain. 2010 Jul;133(Pt 7):2045-57. doi: 10.1093/brain/awq123.
7
Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Brain. 1997 Sep;120 ( Pt 9):1541-52. doi: 10.1093/brain/120.9.1541.
8
Imaging Evidence of Nigrostriatal Degeneration in DYT-PRKRA.
Mov Disord Clin Pract. 2020 Apr 6;7(4):472-474. doi: 10.1002/mdc3.12941. eCollection 2020 May.
9
Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations.
Rev Neurol (Paris). 2016 Aug-Sep;172(8-9):488-502. doi: 10.1016/j.neurol.2016.07.009. Epub 2016 Aug 22.
10
Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia.
Brain. 2010 Jul;133(Pt 7):2058-68. doi: 10.1093/brain/awq120. Epub 2010 Jun 17.
引用本文的文献
1
Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome.
Mov Disord Clin Pract. 2024 Mar;11(3):238-247. doi: 10.1002/mdc3.13959. Epub 2023 Dec 28.
2
Sleep Disorders Associated with Neurodegenerative Diseases.
Diagnostics (Basel). 2023 Sep 10;13(18):2898. doi: 10.3390/diagnostics13182898.
3
Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndrome.
Hum Brain Mapp. 2023 Aug 1;44(11):4239-4255. doi: 10.1002/hbm.26342. Epub 2023 Jun 3.
4
Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers.
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):126-136. doi: 10.1590/0004-282X-ANP-2022-S134.
5
Of Criteria and Men-Diagnosing Atypical Parkinsonism: Towards an Algorithmic Approach.
Brain Sci. 2021 May 25;11(6):695. doi: 10.3390/brainsci11060695.
6
Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review.
Cells. 2021 Jan 15;10(1):171. doi: 10.3390/cells10010171.
7
Tauopathy and Movement Disorders-Unveiling the Chameleons and Mimics.
Front Neurol. 2020 Nov 5;11:599384. doi: 10.3389/fneur.2020.599384. eCollection 2020.
8
Four-Repeat Tauopathies: Current Management and Future Treatments.
Neurotherapeutics. 2020 Oct;17(4):1563-1581. doi: 10.1007/s13311-020-00888-5.
9
Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.
Dtsch Arztebl Int. 2019 Nov 1;116(44):747-754. doi: 10.3238/arztebl.2019.0747.
10
The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.
Alzheimers Dement (N Y). 2019 Oct 14;5:597-609. doi: 10.1016/j.trci.2019.09.005. eCollection 2019.
本文引用的文献
1
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.
Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13.
2
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13.
3
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.
Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.
4
The Differential Diagnosis and Treatment of Atypical Parkinsonism.
Dtsch Arztebl Int. 2016 Feb 5;113(5):61-9. doi: 10.3238/arztebl.2016.0061.
5
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.
Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.
6
Invited review: Neuropathology of tauopathies: principles and practice.
Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23. doi: 10.1111/nan.12208.
7
Distinct tau prion strains propagate in cells and mice and define different tauopathies.
Neuron. 2014 Jun 18;82(6):1271-88. doi: 10.1016/j.neuron.2014.04.047. Epub 2014 May 22.
8
Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.
Acta Neuropathol. 2013 Sep;126(3):365-84. doi: 10.1007/s00401-013-1157-y. Epub 2013 Jul 31.
9
Brain homogenates from human tauopathies induce tau inclusions in mouse brain.
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9535-40. doi: 10.1073/pnas.1301175110. Epub 2013 May 20.
10
Criteria for the diagnosis of corticobasal degeneration.
Neurology. 2013 Jan 29;80(5):496-503. doi: 10.1212/WNL.0b013e31827f0fd1.
Zotero 插件